Shares of Alector, Inc. (NASDAQ:ALEC - Get Free Report) have earned a consensus rating of "Hold" from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $4.00.
Separately, HC Wainwright upped their target price on Alector from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday, May 9th.
Read Our Latest Stock Report on ALEC
Alector Price Performance
ALEC traded down $0.11 during midday trading on Wednesday, hitting $1.61. The stock had a trading volume of 254,301 shares, compared to its average volume of 839,202. The business has a fifty day moving average of $1.39 and a 200 day moving average of $1.45. The company has a quick ratio of 3.34, a current ratio of 3.34 and a debt-to-equity ratio of 0.10. Alector has a 1 year low of $0.87 and a 1 year high of $6.78.
Institutional Trading of Alector
A number of institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new position in shares of Alector during the fourth quarter valued at approximately $18,324,000. 5AM Venture Management LLC bought a new position in shares of Alector during the fourth quarter valued at approximately $1,882,000. Vestal Point Capital LP bought a new position in shares of Alector during the first quarter valued at approximately $621,000. Acadian Asset Management LLC raised its holdings in shares of Alector by 39.8% during the first quarter. Acadian Asset Management LLC now owns 1,440,661 shares of the company's stock valued at $1,768,000 after acquiring an additional 410,205 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Alector by 63.0% during the fourth quarter. Renaissance Technologies LLC now owns 915,738 shares of the company's stock valued at $1,731,000 after acquiring an additional 353,988 shares in the last quarter. Hedge funds and other institutional investors own 85.83% of the company's stock.
About Alector
(
Get Free ReportAlector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.
Featured Articles
Before you consider Alector, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alector wasn't on the list.
While Alector currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
